Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:CGCNASDAQ:CRONNASDAQ:DNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$20.40-1.1%$19.18$15.47▼$36.37$697.95M1.47182,678 shs360,630 shsCGCCanopy Growth$1.83-5.2%$1.23$0.77▼$10.04$336.47M0.795.82 million shs8.14 million shsCRONCronos Group$2.03-1.0%$1.85$1.60▼$2.69$790.08M1.061.30 million shs1.29 million shsDNTHDianthus Therapeutics$18.42+0.3%$19.13$13.37▼$32.27$592.39M1.48273,728 shs234,992 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma0.00%+5.37%-3.64%-24.64%+2.56%CGCCanopy Growth0.00%+10.24%+22.82%+12.27%-80.55%CRONCronos Group0.00%-5.14%+9.73%+3.05%-27.24%DNTHDianthus Therapeutics0.00%-6.45%-13.24%-22.18%-20.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma0.9906 of 5 stars3.60.00.00.01.90.00.0CGCCanopy Growth0.8857 of 5 stars0.52.00.00.02.30.01.3CRONCronos Group0.9834 of 5 stars0.03.00.00.03.30.01.3DNTHDianthus Therapeutics1.2808 of 5 stars3.60.00.00.02.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.14Buy$39.2992.58% UpsideCGCCanopy Growth 1.00Sell$2.009.29% UpsideCRONCronos Group 0.00N/AN/AN/ADNTHDianthus Therapeutics 3.22Buy$53.00187.73% UpsideCurrent Analyst Ratings BreakdownLatest CGC, CRON, DNTH, and AVBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025AVBPArriVent BioPharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/14/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/20/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.003/19/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/12/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.00 ➝ $36.003/12/2025DNTHDianthus TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$84.00 ➝ $84.003/12/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/10/2025AVBPArriVent BioPharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.003/7/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$39.00 ➝ $39.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/ACGCCanopy Growth$276.75M1.22N/AN/A$2.72 per share0.67CRONCronos Group$124.59M6.28N/AN/A$2.87 per share0.71DNTHDianthus Therapeutics$6.52M90.80N/AN/A$11.40 per share1.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$3.77N/AN/AN/AN/A-43.89%-29.67%8/13/2025 (Estimated)CGCCanopy Growth-$487.23M-$3.80N/AN/AN/A-156.98%-56.52%-24.18%5/30/2025 (Confirmed)CRONCronos Group-$73.96M$0.13N/A67.671.74-42.65%-2.56%-2.47%N/ADNTHDianthus Therapeutics-$43.56M-$2.88N/AN/AN/A-1,250.32%-21.68%-20.88%N/ALatest CGC, CRON, DNTH, and AVBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q4 2025CGCCanopy Growth-$0.28N/AN/AN/A$71.84 millionN/A5/12/2025Q1 2025AVBPArriVent BioPharma-$0.66-$1.90-$1.24-$1.90N/AN/A5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million3/11/2025Q4 2024DNTHDianthus Therapeutics-$0.85-$0.81+$0.04-$0.81$1.40 million$1.33 million3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28CGCCanopy Growth0.743.522.58CRONCronos GroupN/A24.2423.05DNTHDianthus TherapeuticsN/A18.3018.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%CGCCanopy Growth3.33%CRONCronos Group8.71%DNTHDianthus Therapeutics47.53%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharmaN/ACGCCanopy Growth1.30%CRONCronos Group7.30%DNTHDianthus Therapeutics8.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.21 millionN/AN/ACGCCanopy Growth3,150183.87 million153.39 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableDNTHDianthus Therapeutics8032.16 million24.70 millionOptionableCGC, CRON, DNTH, and AVBP HeadlinesRecent News About These CompaniesDianthus Therapeutics appoints new board memberMay 24 at 3:32 PM | investing.comNorthern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)May 23 at 3:09 AM | marketbeat.comDianthus Therapeutics Appoints Simon Read, Ph.D., to Board of DirectorsMay 22 at 4:10 PM | globenewswire.comPoint72 Asset Management L.P. Reduces Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)May 22 at 4:42 AM | marketbeat.comVestal Point Capital LP Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)May 21, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Holdings Lifted by Janus Henderson Group PLCMay 18, 2025 | marketbeat.comHC Wainwright Issues Positive Outlook for DNTH EarningsMay 17, 2025 | americanbankingnews.comWedbush Expects Stronger Earnings for Dianthus TherapeuticsMay 17, 2025 | americanbankingnews.comRobert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock PriceMay 15, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from HC WainwrightMay 15, 2025 | marketbeat.comOctagon Capital Advisors LP Raises Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)May 15, 2025 | marketbeat.comDianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC WainwrightMay 15, 2025 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Price Target Lowered to $50.00 at Robert W. BairdMay 15, 2025 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6.1% Following Analyst DowngradeMay 15, 2025 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.com4DNTH : Breaking Down Dianthus Therapeutics: 5 Analysts Share Their ViewsMay 13, 2025 | benzinga.comDianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsMay 12, 2025 | globenewswire.comBraidwell LP Raises Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)May 8, 2025 | marketbeat.comDianthus Therapeutics completes enrollment for MaGic trialMay 6, 2025 | investing.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Avidity Partners Management LPMay 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGC, CRON, DNTH, and AVBP Company DescriptionsArriVent BioPharma NASDAQ:AVBP$20.40 -0.23 (-1.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.40 0.00 (0.00%) As of 05/23/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Canopy Growth NASDAQ:CGC$1.83 -0.10 (-5.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Cronos Group NASDAQ:CRON$2.03 -0.02 (-0.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.03 0.00 (0.00%) As of 05/23/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Dianthus Therapeutics NASDAQ:DNTH$18.42 +0.06 (+0.33%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.42 +0.00 (+0.03%) As of 05/23/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
